Ascendia

  MARKET NEWS

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection 
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
Alzheon Reports Plasma Biomarker Results From Phase 3 & 2 Studies, Validating First-in-Class Mechanism of Action & Underscoring Benefits in Cognition, Function & Brain Volume Protection in Alzheimer’s Patients
Sanofi’s Venglustat Met All Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease
MGS Launches A.i.r. Platform, Delivering New Levels of Design Flexibility for Auto-Injectors
Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
PhaseV Launches AI-Powered Enrollment Lab: Eliminating Guesswork & Grounding Study Design in Clinical Reality
Ardena Completes Divestment of its Södertälje Drug Substance Site in Sweden to Nanologica
Vetter Pharma to Build New Manufacturing Site in Germany
ENA Respiratory Announces Dosing of First Participants in Phase II Study of Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

  EXPERT CONTENT & RESOURCES

Antibody Validation: The Hidden Key to Reproducible Drug Discovery

Antibody Validation: The Hidden Key to Reproducible Drug Discovery

As research grows more complex and data-driven, rigorous antibody validation is increasingly recognized as a critical requirement for ensuring data integrity and improving the predictive power of drug discovery pipelines.

From Concept to Optimization: A Step-by-Step Guide to SEDDS for Enhanced Oral Bioavailability

From Concept to Optimization: A Step-by-Step Guide to SEDDS for Enhanced Oral Bioavailability

Join Dr. Masumi Dave, Application Lab Manager at Gattefossé USA, for a practical, step-by-step guide to developing optimized Self-Emulsifying Drug Delivery Systems (SEDDS). This webinar provides a proven framework you can apply in your lab to overcome solubility and permeability challenges with lipid excipients.

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

This paper explores practical approaches for identifying and mitigating nitrosamine risks in drug products, integrating emerging tools such as predictive machine learning, advanced nitrite testing methodologies, and strategic excipient sourcing.

Dr. Joseph Sinkule, Founder, Chairman of the Board and CEO of Klotho Neurosciences

Klotho Neurosciences: Focused on Neurodegenerative & Age-Related Disorders

Dr. Joseph Sinkule, CEO of Klotho Neurosciences, discusses the company, its therapies, the human Klotho gene, and longevity.

  FEATURED EDITORIAL

  COMPANY PROFILE

For over 35 years, DDL has provided extraordinary service and specialized testing expertise to the medical device and pharmaceutical industries. Our reliable quality, responsive attention, and on-schedule completion for packaging, medical device, and combination products testing secures confidence in performance and safety while achieving regulatory compliance. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Revolutionizing Small Molecule API Production: Unveiling the Impact of Fermentation as a Sustainable Solution

WHITEPAPER - Revolutionizing Small Molecule API Production: Unveiling the Impact of Fermentation as a Sustainable Solution

While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lines blurring between traditional chemical synthesis …

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 11 – Injection Devices
February 18 – Formulation Development